It has also been confirmed that pinometostat is undergoing a phase 1/2 clinical trial for evaluating the combination of pinometostat and standard chemotherapy for the treatment of newly diagnosed MLL rearranged leukemia in children and adults (NCT03724084) (Lonetti et al., 2019). Here, KMT2A is linked to leukemia.